ReviewRSC advances2025
Polymeric nanomaterials as a drug delivery system for anticancer and antibacterial infections: a review.
Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Bio-based nanomaterials in drug delivery: An updated review.Pharmaceutical science advances · 2026Review
- Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole-curcumin nanocomplex through TLR2-FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer.Scientific reports · 2026Article
- Experimental Models and Nanotechnology-Based Platforms in Oral Squamous Cell Carcinoma: From Tumor Biology to Translational Applications.Pharmaceutics · 2026Review
- Versatile Targeted Celastrol Nanoassemblies for Enhanced Immunomodulatory Effects Against MRSA Infection.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Smart nanoparticle vaccines integrate nanotechnology artificial intelligence and immunoengineering for precision immunization.Discover nano · 2026Review
- Emerging paradigms in nanostructured targeted drug delivery systems.Discover nano · 2026Review
- Polymer Nanoparticles in Medical Applications-Future Directions.Nanomaterials (Basel, Switzerland) · 2026Review
- Synthesis and biological study of thiopheneyl/piperazinl-α-aminophosphonate-chitosan conjugates as biologically active carriers for controlled delivery of curcumin.Scientific reports · 2026Article
- Nanomedicine against antimicrobial resistance: mechanistic insights and next-generation therapeutic potential.Frontiers in chemistry · 2026Review
- A Hemoglobin-Based Nanoparticle Delivery System Enhances the Pharmacokinetics and Efficacy of Tigecycline inBME frontiers · 2026Article
- Sustainable nanomedicine:green synthesis of functional nanomaterials and its applications.Frontiers in chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, cancer remains the primary cause of mortality. Despite significant progress in cancer research, the efficacy of chemotherapy has diminished in recent decades due to the emergence of multidrug resistance. Conventional cancer treatments such as radiation, chemotherapy, and surgical interventions often result in morbidity and inadequate cure rates for various cancer types. Bacterial infections also pose a growing therapeutic challenge, primarily due to their inherent characteristics, increasing antibiotic resistance, and the increasing number of immunocompromised individuals. Polymeric nanoparticles (NPs) serve as crucial tools for improving targeted drug delivery at the site of action and enhancing drug bioavailability. Polymers may be an optimal choice because of their versatility in meeting the specific requirements of each drug delivery system. This review encompasses polymeric nanoparticles for cancer drug delivery, polymeric nanoparticles for antibacterial drug delivery, types of biodegradable polymeric nanoparticles, and the functions of polymeric nanoparticles in various routes of drug administration.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.